Findings

What do systematic reviews say?

3 questions · 4 findings · 2 reviews · Hepato-Biliary

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 3 · 75%Low 1 · 25%Moderate 0 · 0%High 0 · 0%

Peginterferon alpha‐2a vs peginterferon alpha‐2b

All other (non‐serious) adverse events · people with chronic hepatitis C

1 finding from 1 review

Peginterferon alpha‐2a versus peginterferon alpha‐2b for chronic hepatitis C 2014 · Cochrane Headline outcomes only
no estimate extracted
9 studies · 4981 participants
Very low

Peginterferon alpha‐2a vs peginterferon alpha‐2b

Serious adverse events Number of events · people with chronic hepatitis C

Peginterferon alpha‐2a showed no clear difference in serious adverse events Number of events compared with peginterferon alpha‐2b (low certainty).

1 finding from 1 review

Peginterferon alpha‐2a versus peginterferon alpha‐2b for chronic hepatitis C 2014 · Cochrane Headline outcomes only
RR 1.12 [0.95, 1.3]
4 studies · 3900 participants
Low

Intervention vs no intervention or control intervention (control)

Serious adverse events (number) ‐ pegylated interferon‐alpha plus ribavirin versus pegylated interferon‐alpha · people with acute hepatitis C infection

It is very uncertain whether intervention changes serious adverse events (proportion) ‐ pegylated interferon‐alpha… compared with no intervention or control intervention (control) (very low certainty).

2 findings from 1 review

Pharmacological interventions for acute hepatitis C infection 2018 · Cochrane Headline outcomes only
OR 1.72 [0.7, 4.21]
2 studies · 237 participants
Very low
Pharmacological interventions for acute hepatitis C infection 2018 · Cochrane Headline outcomes only
Rate ratio 2.74 [1.4, 5.33]
2 studies · 237 participants
Very low